AMARIN BEGINS EUROPEAN CLINICAL TRIAL FOR MIRAXION

December 16, 2005

Amarin has announced that the European Phase III clinical trial of Miraxion
in Huntington's disease has commenced. A similar U.S. Phase III clinical trial
began dosing in September.

The U.S. and European trials are multicenter, randomized, double blind, placebo-controlled
studies of Miraxion at 43 sites in the U.S. and up to 33 sites in Europe. The
trials are planned to enroll 540 Huntington's disease patients, with approximately
300 in the U.S. trial and approximately 240 in the European trial over a six-month
period. Patients in the U.S. trial will participate in a further six-month extension
period.